MiNK Therapeutics, Inc. (INKT) Stock Analysis & Investment Frameworks
MiNK Therapeutics, Inc. (INKT) stock analysis on Invetso. Review MiNK Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
MiNK Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
MiNK Therapeutics, Inc. Key Financial Metrics
- Market Cap: $52.82M
- Revenue: $N/A
- ROE: 83.45%
- ROIC: -604.20%
- Dividend Yield: N/A
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
MiNK Therapeutics, Inc. Investment Frameworks
Invetso analyzes MiNK Therapeutics, Inc. (INKT) across the following frameworks:
- MiNK Therapeutics, Inc. 10Y Growth Potential
- MiNK Therapeutics, Inc. Scenario Analysis
- MiNK Therapeutics, Inc. Risks & Opportunities
- MiNK Therapeutics, Inc. Economic Moat
- MiNK Therapeutics, Inc. Business Model
- MiNK Therapeutics, Inc. Management
- MiNK Therapeutics, Inc. SWOT Analysis
- MiNK Therapeutics, Inc. Porter's 5 Forces
- MiNK Therapeutics, Inc. PESTLE Analysis
- MiNK Therapeutics, Inc. ESG Analysis